Candelasa, Cleofe H.
HRN: 21-37-03 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/23/2022
CEFUROXIME 1.5GM (VIAL)
05/23/2022
05/24/2022
IVT
1.5gm
Q8 X 3 Doses
Post-op TAHBSO
Waiting Final Action
Indication: Prophylaxis Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes